Pfizer's Inspra helps heart-attack patients in trial; Brazil's Hypermarcas admits slow sales so far;

 @FiercePharma: That Novartis probe is responding to criminal complaints about lack of disclosure, per BloombergMore | Follow @FiercePharma

 @EricPFierce: Baxter Intl. investing more into international manufacturing, this time in Puerto Rico but it means 400 fewer jobs. Article | Follow @EricPFierce

> Brazil's Hypermarcas has started 2013 with weaker-than-expected sales but still expects to meet its target for operating profits this year, its CEO said. Report

> Pfizer's ($PFE) Inspra may help improve outcomes in patients who have experienced a particular type of heart attack known as STEMI, a study found. Report

> European regulators say new labeling requirements for drugs deemed risky should take effect in September as originally planned. Report

> Protection against whooping cough weakens a few years after small children receive their final booster vaccination against it. Report

Medical Device News

 @FierceMedDev: Stryker slapped with FDA warning letter. More | Follow @FierceMedDev

 @MarkHFierce: St. Jude Medical is releasing a next-gen stent imaging system in Japan, hoping to propel major interest. Article | Follow @MarkHFierce

 @DamianFierce: Cancer Genetics IPO target keeps falling, from $41.9M to $29.3M to $20.1M and, now, just $14.3M. Report | Follow @DamianFierce

> Decision Diagnostics challenges J&J with diabetes test. Story

> Early-stage Alzheimer's blood test on U.K. team's agenda. More

> Crescendo rolls out iPhone app for RA Dx. Item

Biotech News

 @FierceBiotech: In case you missed it: Medtronic, Edwards headline this year's ACC news. Roundup | Follow @FierceBiotech

 @JohnCFierce: Another high flying cancer drug developer looks like a takeover. Puma turns Pfizer castoff into gold. Report | Follow @JohnCFierce

 @RyanMFierce: Shire has acquired Premacure AB for drug against rare eye disease. Release | Follow @RyanMFierce

> Analysts cheer decision to continue Merck's controversial Vytorin study. Article

> Puma Biotech shares roaring up amid M&A meow. Story

> Astellas dumps $390M pact with Ambit on eve of IPO. News

> Omthera files $75M IPO as it blueprints omega-3 drug launch. More

Pharma Manufacturing News

> Marken pushes international expansion with warehouse in China. Item

> Pfizer, Glaxo, others give Interpol money to fight counterfeiters. Report

> Catalent deals target China from 2 directions. Story

Biotech Research News

 @EmilyMFierce: The origin of ovarian cancer has evaded scientists, but researchers at Cornell may have found a possible source. More | Follow @EmilyMFierce

> New therapy shows promise in treating inflammatory breast cancer. Report

> Deleting a gene in mice prevents obesity. Article

> Salt may be risk factor for MS, other autoimmune diseases. Story

> Buildup of unwanted proteins may lead to dementia. Item

And Finally... Some experts defend niacin treatment for heart disease despite the results of a new study. Report

Suggested Articles

How long can one infusion of CAR-T drug Yescarta continue helping patients with refractory large B-cell lymphoma? Pretty long, Gilead showed Saturday.

AbbVie and Roche have fielded their fair share of questions about how well their fixed-duration regimen of Venclexta and Rituxan can keep CLL at bay.

Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.